UA94044C2 - Применение бензоильного производного 3-аминокарбазола для лечения нарушения, связанного с производством простагландина e2 (pge2) - Google Patents

Применение бензоильного производного 3-аминокарбазола для лечения нарушения, связанного с производством простагландина e2 (pge2)

Info

Publication number
UA94044C2
UA94044C2 UAA200713598A UAA200713598A UA94044C2 UA 94044 C2 UA94044 C2 UA 94044C2 UA A200713598 A UAA200713598 A UA A200713598A UA A200713598 A UAA200713598 A UA A200713598A UA 94044 C2 UA94044 C2 UA 94044C2
Authority
UA
Ukraine
Prior art keywords
aminocarbazole
benzoyl derivative
treatment
disorder associated
prostaglandin production
Prior art date
Application number
UAA200713598A
Other languages
English (en)
Ukrainian (uk)
Inventor
Лоренцо Поленцани
Джорджина Мангано
Изабелла Колетта
Мария Алессандра Алиси
Никола Каццолла
Гвидо Фурлотти
Катерина Мауджери
Original Assignee
Ацьенде Кимике Риуните Анджелини Франческо А.Чи.Р.А.Ф. С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ацьенде Кимике Риуните Анджелини Франческо А.Чи.Р.А.Ф. С.П.А. filed Critical Ацьенде Кимике Риуните Анджелини Франческо А.Чи.Р.А.Ф. С.П.А.
Publication of UA94044C2 publication Critical patent/UA94044C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Изобретение относится к области медицины и касается применения бензоильного производного3-аминокарбазола для получения медикамента для профилактического или терапевтического лечения нарушения, выбранного из группы, которая включает воспалительные процессы, воспалительную боль, лихорадку, опухоли, болезнь Альцгеймера и атеросклероз. Изобретение также касается способа профилактического или терапевтического лечения указанных нарушений.
UAA200713598A 2005-05-19 2006-05-03 Применение бензоильного производного 3-аминокарбазола для лечения нарушения, связанного с производством простагландина e2 (pge2) UA94044C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000909A ITMI20050909A1 (it) 2005-05-19 2005-05-19 Uso di un benzoil derivato dal 3-ammino-carbazolo per la produzione di un farmaco per il trattamento di un disturbo associato alla produzione di prostaglandina e2-pge2-
PCT/EP2006/004348 WO2006122680A1 (en) 2005-05-19 2006-05-03 Use of a benzoyl derivative of 3-aminocarbazole for the treatment of a disorder associated with the production of prostaglandin e2 (pge2)

Publications (1)

Publication Number Publication Date
UA94044C2 true UA94044C2 (ru) 2011-04-11

Family

ID=35219704

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200713598A UA94044C2 (ru) 2005-05-19 2006-05-03 Применение бензоильного производного 3-аминокарбазола для лечения нарушения, связанного с производством простагландина e2 (pge2)

Country Status (23)

Country Link
US (1) US8686021B2 (ru)
EP (1) EP1881826B1 (ru)
JP (1) JP5086991B2 (ru)
KR (1) KR101312579B1 (ru)
CN (1) CN101166528B (ru)
AR (1) AR054126A1 (ru)
AT (1) ATE473739T1 (ru)
AU (1) AU2006246688B2 (ru)
BR (1) BRPI0609718A2 (ru)
CA (1) CA2604562C (ru)
DE (1) DE602006015457D1 (ru)
DK (1) DK1881826T3 (ru)
EA (1) EA012724B1 (ru)
ES (1) ES2347174T3 (ru)
GE (1) GEP20094738B (ru)
IL (1) IL186072A (ru)
IT (1) ITMI20050909A1 (ru)
MX (1) MX2007013491A (ru)
PL (1) PL1881826T3 (ru)
PT (1) PT1881826E (ru)
SI (1) SI1881826T1 (ru)
UA (1) UA94044C2 (ru)
WO (1) WO2006122680A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20051523A1 (it) 2005-08-03 2007-02-04 Acraf Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo
EP2119705A1 (en) * 2008-05-14 2009-11-18 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. 3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor
US9313791B2 (en) 2009-05-14 2016-04-12 Qualcomm Incorporated System and method for dropping and adding an air interface in a wireless communication system

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002241368A (ja) * 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
US6399631B1 (en) * 1999-07-23 2002-06-04 Pfizer Inc. Carbazole neuropeptide Y5 antagonists
WO2001007409A1 (en) 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
WO2001013917A1 (en) * 1999-08-26 2001-03-01 Bristol-Myers Squibb Company Npy antagonists: spiroisoquinolinone derivatives
DE10125961A1 (de) * 2001-05-29 2002-12-12 Boehringer Ingelheim Int Carbazolderivate und deren Verwendung zur Herstellung einer Arzneimittelzusammensetzung zur Behandlung von im Zusammenhang mit NPY stehenden Leiden
CA2403307A1 (en) * 2001-10-23 2003-04-23 Neurogen Corporation Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives
KR20030042344A (ko) * 2001-11-22 2003-05-28 한국생명공학연구원 에레모필란계 화합물 또는 곰취추출물을 유효성분으로함유하는 염증질환 치료제, 면역질환 치료제, 및 암 치료제
ES2193875B2 (es) * 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
KR100402714B1 (ko) * 2002-12-23 2003-11-13 한국생명공학연구원 디테르펜계 화합물을 염증질환, 면역질환 및 암 치료제로사용하는 신규한 용도

Also Published As

Publication number Publication date
MX2007013491A (es) 2008-01-24
HK1119571A1 (en) 2009-03-13
DE602006015457D1 (de) 2010-08-26
ES2347174T3 (es) 2010-10-26
AR054126A1 (es) 2007-06-06
EA200702534A1 (ru) 2008-04-28
EP1881826A1 (en) 2008-01-30
US20080287518A1 (en) 2008-11-20
CN101166528A (zh) 2008-04-23
ATE473739T1 (de) 2010-07-15
GEP20094738B (en) 2009-07-27
IL186072A (en) 2012-05-31
IL186072A0 (en) 2008-08-07
SI1881826T1 (sl) 2010-10-29
KR101312579B1 (ko) 2013-09-30
AU2006246688B2 (en) 2011-09-22
PT1881826E (pt) 2010-08-05
CA2604562A1 (en) 2006-11-23
WO2006122680A1 (en) 2006-11-23
PL1881826T3 (pl) 2010-12-31
CN101166528B (zh) 2011-06-15
CA2604562C (en) 2013-09-17
EA012724B1 (ru) 2009-12-30
JP2008540591A (ja) 2008-11-20
DK1881826T3 (da) 2010-11-01
BRPI0609718A2 (pt) 2011-10-18
EP1881826B1 (en) 2010-07-14
KR20080018898A (ko) 2008-02-28
AU2006246688A1 (en) 2006-11-23
US8686021B2 (en) 2014-04-01
ITMI20050909A1 (it) 2006-11-20
JP5086991B2 (ja) 2012-11-28

Similar Documents

Publication Publication Date Title
CR20240003A (es) Restos de administración terapéutica novedosos y usos de estos
MX2012005131A (es) Enfoques terapeuticos nuevos para tratar la enfermedad de alzheimer.
NO20071267L (no) Forhindring og behandling av synukleinopatiske og amyloidogene sykdommer
SMT201300095B (it) Uso dell'estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia
MX2010004614A (es) Composiciones para tratamiento del mal de parkinson.
IL219857A0 (en) Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis
UA99309C2 (ru) Замещенные пиперидинодигидротиенопиримидины
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
NZ606825A (en) Methods and compositions for treating complement-associated disorders
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
UA102541C2 (ru) Соединение 3-аминокарбазола, фармацевтическая композиция, которая его содержит, и способ его получения
EA201000914A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
EA201071244A1 (ru) Новые терапевтические подходы в лечении болезни альцгеймера и обусловленных ею расстройств посредством модуляции ангиогенеза
EA201000365A1 (ru) Гетероциклические амиды, пригодные для лечения злокачественного новообразования и псориаза
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
EP2583978A3 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
MY145439A (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
MX2007001679A (es) Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
UA96447C2 (ru) Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы
SE0400184D0 (sv) New therapeutical use
ATE516366T1 (de) Regulierte aptamer-therapeutika
PL2244703T3 (pl) Lekarstwo, jego wytwarzanie i zastosowanie w leczeniu bolesnych neuropatii
WO2008066626A3 (en) METHODS FOR THE TREATMENT OF Aβ RELATED DISORDERS AND COMPOSITIONS THEREFOR
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
TW200733976A (en) Method for the treatment of cognitive dysfunction